| Biomarker ID | 892 |
| PMID | 22452941 |
| Year | 2012 |
| Biomarker | Methylation Status of HOXD3 |
| Biomarker Basis | Methylation Based |
| Biomolecule | Methylation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 2.211 (95% CI: 1.098-4.450) |
| Effect on Pathways | Pathways include (HOXD3): T cell receptor regulation of apoptosis |
| Experiment | Pathological Stage (pT2 Vs pT3/pT4) |
| Type of Biomarker | Prognostic |
| Cohort | 253 patients with prostate cancer, with 76 cases with Biochemical Recurrence. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.026 |
| Method Used | ERG Fusion Status: Immunohistochemistry; Methylation Status: quantitative MethyLight assay |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | HOXD3 |